Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)


Demirci U., Tufan G., Aktas B., Balakan O., ALACACIOĞLU A., Dane F., ...More

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.139, no.5, pp.829-835, 2013 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 139 Issue: 5
  • Publication Date: 2013
  • Doi Number: 10.1007/s00432-013-1390-8
  • Title of Journal : JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Page Numbers: pp.829-835

Abstract

The overall prognosis for recurrent malignant glioma (MG) is extremely poor, and treatment options are limited. We evaluated our multicenter retrospective experience for patients with recurrent MG administering bevacizumab and irinotecan in combination therapy.